EP4352065A1 - Process for producing biotin intermediate - Google Patents

Process for producing biotin intermediate

Info

Publication number
EP4352065A1
EP4352065A1 EP21944658.0A EP21944658A EP4352065A1 EP 4352065 A1 EP4352065 A1 EP 4352065A1 EP 21944658 A EP21944658 A EP 21944658A EP 4352065 A1 EP4352065 A1 EP 4352065A1
Authority
EP
European Patent Office
Prior art keywords
cyanide
compound
mol
formula
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21944658.0A
Other languages
German (de)
French (fr)
Inventor
Werner Bonrath
Bo Gao
Kun Peng
Qiong-mei ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of EP4352065A1 publication Critical patent/EP4352065A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention is related to a process for producing an important biotin intermediate.
  • the D ⁇ Biotin also known as Vitamin H, is mainly applied to the fields of medicine and sanitation, nutrition enhancer, feed additive, cosmetics and drinks, etc.
  • the molecular structural formula of the D ⁇ Biotin is shown as follows:
  • a known process for producing the above compound (a) comprises: a) L ⁇ cysteine or L ⁇ serine is used as raw material to produce an optically active hydantoin which is then converted to an intermediate compound (IX) , b) the intermediate compound (IX) is converted into a bicyclic cyanohydantoin (I) in two steps, and c) the bicyclic cyanohydantoin (I) is finally converted to the compound (a) in additional two steps.
  • step b) is critical but it has two steps and uses expensive catalysts and reagents. As a result, the process is not good enough for industry.
  • the present invention provides an improved process for producing a biotin intermediate compound (I) ,
  • R 1 and R 2 are each independently of one another H, lower alkyl, lower cycloalkyl, aryl, or lower aralkyl, optionally substituted by one or more substituents;
  • R 3 is H, or a protective group which is suitable for a nitrogen atom
  • X and Y are each independently of one another O or S.
  • the process of the present application reduces the steps for producing the compound of formula (I) , and more importantly reduces cost by avoiding expensive catalysts and reagents and provides high yield and/or selectivity.
  • lower alkyl refers to C 1 ⁇ C 10 alkyl, i.e., branched or unbranched, cyclic or non ⁇ cyclic, saturated hydrocarbon comprising 1 ⁇ 10 carbon atoms.
  • the “lower alkyl” is C 1 ⁇ C 6 alkyl, including but not limited to methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert ⁇ butyl, cyclobutyl, pentyl, iso ⁇ pentyl, tert ⁇ pentyl, cyclopentyl, hexyl, isohexyl, tert ⁇ hexyl, cyclohexyl, octyl, isooctyl, tert ⁇ octyl, cyclooctyl, nonyl, isononyl, tert ⁇ nonyl, cyclononyl, decyl, isodecyl, tert ⁇ decyl, cyclodecyl. More preferably, the “lower alkyl” is methyl or ethyl.
  • aryl refers to a carbocyclic aromatic system containing one ring, or two or three rings fused together where in the ring atoms are all carbon.
  • aryl includes, but is not limited to groups such as phenyl, benzyl, xylyl and naphthalenyl.
  • lower cycloalkyl refers to a saturated monocyclic, bicyclic or tricyclic group wherein the ring atoms of the cyclic system are all carbon and wherein each cyclic moiety contains from 3 to 12 carbon atom ring members.
  • One group of lower cycloalkyl has from 5 to 7 carbon atoms. Examples of lower cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.
  • lower aralkyl refers to an aryl attached to the parent molecular moiety through a lower alkyl, wherein the aryl and the lower alkyl are defined herein.
  • lower silyl refers to a structure represented by R 1 R 2 R 3 Si ⁇ wherein R 1 , R 2 and R 3 are each independently of one another lower alkyl or aryl as defined herein.
  • lower alkoxyl refers to the structure represented by (lower alkyl) ⁇ O ⁇ , wherein the lower alkyl is as defined herein.
  • halo or “halogen” as used refers to a group of elements including fluorine (F) , chlorine (Cl) , bromine (Br) and iodine (I) , preferably refers to Cl or Br.
  • halide as used is meant to include iodide, bromide, chloride and fluoride, and preferably bromide or iodide, and more preferably bromide.
  • substituteduent or “substituents” as used refers to lower alkyl, lower alkoxyl, hydroxyl, halo, ⁇ NH 2 , ⁇ NO 2 , cyano and/or isocyano.
  • the symbol as used in the compound formulas of the present invention means the connected group is connected to a chiral carbon in S ⁇ and/or R ⁇ configuration.
  • the present invention provides a process for producing a compound of formula (I) , or a stereoisomer thereof, or a stereoisomeric mixture thereof, comprising reacting a compound of formula (II) , or a stereoisomer thereof, or a stereoisomeric mixture thereof, with a cyanide in the presence of an amide solvent,
  • R 1 and R 2 are each independently of one another H, lower alkyl, lower cycloalkyl, aryl, or lower aralkyl, optionally substituted by one or more substituents;
  • R 3 is H, or a protective group which is suitable for a nitrogen atom
  • R 4 is H, lower alkyl, lower silyl, acyl, lower alkyl sulfonyl, arylsulfonyl, or lower aralkyl sulfonyl, optionally substituted by one or more substituents;
  • X and Y are each independently of one another O or S.
  • the cyanide may be a metal cyanide such as sodium cyanide (NaCN) , potassium cyanide (KCN) , zinc cyanide and copper cyanide.
  • NaCN sodium cyanide
  • KCN potassium cyanide
  • the cyanide is sodium cyanide or potassium cyanide.
  • the amide solvent is preferably formamide or acetamide. More preferably, the amide solvent is formamide.
  • the protective group may be tert ⁇ butyl, benzyl, 4 ⁇ methoxybenzyl, 3, 4 ⁇ dimethoxybenzyl, 4 ⁇ methylbenzyl, allyl, methallyl, crotyl, methoxymethyl, trimethylsilyl, tert ⁇ butyldimethylsilyl, or tert ⁇ butyldiphenylsilyl.
  • R 1 and R 2 are, each independently of one another, preferably H, C 1 ⁇ C 6 alkyl, or phenyl or benzyl, optionally substituted by one or more substituents, and more preferably R 1 is H and R 2 is phenyl.
  • R 3 is preferably tert ⁇ butyl or benzyl, optionally substituted by one or more substituents, more preferably, R 3 is benzyl.
  • R 4 is preferably H, methyl, ethyl, trifluoromethyl, bistrifluoromethylmethyl, trimethylsilyl ( ⁇ TMS) , formyl, acetyl, propionyl, benzoyl, 4 ⁇ nitrobenzoyl, methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, phenylsulfonyl, toluenesulfonyl or benzylsulfonyl.
  • ⁇ TMS trimethylsilyl
  • R 4 is H, acetyl, propionyl, benzoyl, toluenesulfonyl, bistrifluoromethylmethyl or trifluoromethanesulfonyl.
  • R 4 is H, benzoyl or acetyl.
  • R 1 is H
  • R 2 is phenyl
  • R 3 is benzyl
  • R 4 is H
  • X is S
  • Y is O.
  • R 1 is H
  • R 2 is phenyl
  • R 3 is benzyl
  • R 4 is benzoyl, bistrifluoromethyl or acetyl
  • X is S
  • Y is O.
  • the stereoisomer of the present invention includes enantiomers and diastereomers.
  • the compound of the formula (I) has the following stereoisomers:
  • R 4 is defined as above.
  • the compound of the formula (I) is one of the following stereoisomers:
  • the compound of the formula (II) is one of the following stereoisomers:
  • the cyanide may be added in an amount of from 1 mol to 20 mol, preferably from 1.5 mol to 15 mol, more preferably from 2 mol to 10 mol, per 1 mole of the compound of formula (II) .
  • the solvent may be used in the reaction in an amount of from 1 mL to 30 mL, preferably from 2 mL to 20 mL, more preferably from 2 mL to 10 mL, per 1 mole of the compound of formula (II) .
  • the reaction is carried out in the absence of a catalyst.
  • the present invention may also be carried out in the presence of a catalyst.
  • the catalyst may be selected from a group consisting of trifluoromethanesulfonic acid (HOTf) , trifluoromethanesulfonate esters such as trimethylsilyl trifluoromethanesulfonate (TMSOTf) and tert ⁇ butyldimethylsilyl trifluoromethanesulfonate (t ⁇ BuMe 2 SiOTf) , trifluoromethanesulfonate salts such as zinc trifluoromethanesulfonate (Zn (OTf) 2 ) , iron trifluoromethanesulfonate (Fe (OTf) 3 ) , copper trifluoromethanesulfonate (Cu (OTf) 2 ) , ytterbium trifluoromethanesulfonate (Yb (OTf)
  • HATf tri
  • an auxiliary reagent may be added into the reaction.
  • suitable auxiliary reagent include but are not limited to ammonium chloride, potassium iodide, tetrabutylammonium bromide, 18 ⁇ Crown ⁇ 6, 4 ⁇ Dimethylaminopyridine, and acetic anhydride, and mixture thereof.
  • the reaction of the process of the present invention may be carried out at the temperature of from 0°Cto 200°C, preferably from 10°C to 180°C, more preferably 20°C to 150°C, such as 50°C to 120°C such as 50 °C, 60 °C, 80 °C, 100 °C or 120°C, and the most preferably 60°C to 80°C.
  • the obtained compound of the formula (I) may be isolated and/or purified by a well ⁇ known process in the art and used for the preparation of (+) ⁇ biotin. Accordingly, the present invention also provides a process for producing (+) ⁇ biotin which comprises the process for producing the compound of formula (I) as described herein.
  • the process of the present application avoids expensive cyanide reagents and catalysts and provides high yield and/or selectivity.
  • Entries Condition Conversion selectivity 1 60°C, for 6h 34% 99.9% 2 80°C, for 3h 68 % 89.3 % 3 120°C, for 1h 100 % 68.3 %

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Provided is an improved process for producing a biotin intermediate compound (I) with low cost and high yield and/or selectivity, Wherein: R 1 and R 2 are each independently of one another H, lower alkyl, lower cycloalkyl, aryl, or lower aralkyl, optionally substituted by one or more substituents; R3 is H, or a protective group which is suitable for a nitrogen atom; and X and Y are each independently of one another O or S.

Description

    [Title established by the ISA under Rule 37.2] PROCESS FOR PRODUCING BIOTIN INTERMEDIATE Technical Field
  • The present invention is related to a process for producing an important biotin intermediate.
    • Background of the Invention
  • The D‐Biotin, also known as Vitamin H, is mainly applied to the fields of medicine and sanitation, nutrition enhancer, feed additive, cosmetics and drinks, etc. The molecular structural formula of the D‐Biotin is shown as follows:
  • Since the debut of industrially synthetized D‐biotin of a Swiss company Roche in 1949, the synthesis methods have been still undergone many researches in the world. To date, many about total synthesis routes have been reported. Yet, the most industrial process for D‐biotin uses thiolactone compounds (a) to produce the intermediate compound (b) which is then converted by catalytic hydrogenation to the compound (c) and finally to the D‐biotin (see US 3,740,416) .
  • A known process for producing the above compound (a) comprises: a) L‐cysteine or L‐serine is used as raw material to produce an optically active hydantoin which is then converted to an intermediate compound (IX) , b) the intermediate compound (IX) is converted into a bicyclic cyanohydantoin (I) in two steps, and c) the bicyclic cyanohydantoin (I) is finally converted to the compound (a) in additional two steps. (see US 5,095,118 A)
  • In the above process, the step b) is critical but it has two steps and uses expensive catalysts and reagents. As a result, the process is not good enough for industry.
  • Accordingly, there is still demand in a process for producing the biotin intermediate compound (I) with improved cost, yield and/or selectivity.
  • Summary of the Invention
  • The present invention provides an improved process for producing a biotin intermediate compound (I) ,
  • Wherein:
  • R 1 and R 2 are each independently of one another H, lower alkyl, lower cycloalkyl, aryl, or lower aralkyl, optionally substituted by one or more substituents;
  • R 3 is H, or a protective group which is suitable for a nitrogen atom; and
  • X and Y are each independently of one another O or S.
  • The process of the present application reduces the steps for producing the compound of formula (I) , and more importantly reduces cost by avoiding expensive catalysts and reagents and provides high yield and/or selectivity.
    • Detailed Description of the Invention
  • In the present invention, the term “lower alkyl” as used refers to C 1‐C 10 alkyl, i.e., branched or unbranched, cyclic or non‐cyclic, saturated hydrocarbon comprising 1‐10 carbon atoms. Preferably, the “lower alkyl” is C 1‐C 6 alkyl, including but not limited to methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert‐butyl, cyclobutyl, pentyl, iso‐pentyl, tert‐pentyl, cyclopentyl, hexyl, isohexyl, tert‐hexyl, cyclohexyl, octyl, isooctyl, tert‐octyl, cyclooctyl, nonyl, isononyl, tert‐nonyl, cyclononyl, decyl, isodecyl, tert‐decyl, cyclodecyl. More preferably, the “lower alkyl” is methyl or ethyl.
  • In the present invention, the term “aryl” as used refers to a carbocyclic aromatic system containing one ring, or two or three rings fused together where in the ring atoms are all carbon. The term “aryl” includes, but is not limited to groups such as phenyl, benzyl, xylyl and naphthalenyl.
  • In the present invention, the term “lower cycloalkyl” as used refers to a saturated monocyclic, bicyclic or tricyclic group wherein the ring atoms of the cyclic system are all carbon and wherein each cyclic moiety contains from 3 to 12 carbon atom ring members. One group of lower cycloalkyl has from 5 to 7 carbon atoms. Examples of lower cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.
  • In the present invention, the term “lower aralkyl” as used refers to an aryl attached to the parent molecular moiety through a lower alkyl, wherein the aryl and the lower alkyl are defined herein.
  • In the present invention, the term “acyl” as used refers to a structure represented by R‐C (=O) ‐wherein R is lower alkyl or aryl as defined herein.
  • In the present invention, the term “lower silyl” as used refers to a structure represented by R 1R 2R 3Si‐wherein R 1, R 2 and R 3 are each independently of one another lower alkyl or aryl as defined herein.
  • In the present invention, the term “lower alkyl sulfonyl” as used refers to a structure represented by (lower alkyl) ‐S (=O)  2‐wherein the lower alkyl is as defined herein.
  • In the present invention, the term “arylsulfonyl” as used refers to a structure represented by aryl‐S (=O)  2‐wherein the aryl is as defined herein.
  • In the present invention, the term “lower aralkyl sulfonyl” as used refers to a structure represented by (lower aralkyl) ‐S (=O)  2‐wherein the lower aralkyl is as defined herein.
  • In the present invention, the term “lower alkoxyl” as used refers to the structure represented by (lower alkyl) ‐O‐, wherein the lower alkyl is as defined herein.
  • In the present invention, the term “halo” or “halogen” as used refers to a group of elements including fluorine (F) , chlorine (Cl) , bromine (Br) and iodine (I) , preferably refers to Cl or Br.
  • In the present invention, the term “halide” as used is meant to include iodide, bromide, chloride and fluoride, and preferably bromide or iodide, and more preferably bromide.
  • In the present invention, the term “substituent” or “substituents” as used refers to lower alkyl, lower alkoxyl, hydroxyl, halo, ‐NH 2, ‐NO 2, cyano and/or isocyano.
  • In the present invention, the symbol as used in the compound formulas of the present invention means the connected group is connected to a chiral carbon in S‐and/or R‐configuration.
  • The present invention provides a process for producing a compound of formula (I) , or a stereoisomer thereof, or a stereoisomeric mixture thereof, comprising reacting a compound of formula (II) , or a stereoisomer thereof, or a stereoisomeric mixture thereof, with a cyanide in the presence of an amide solvent,
  • Wherein:
  • R 1 and R 2 are each independently of one another H, lower alkyl, lower cycloalkyl, aryl, or lower aralkyl, optionally substituted by one or more substituents;
  • R 3 is H, or a protective group which is suitable for a nitrogen atom;
  • R 4 is H, lower alkyl, lower silyl, acyl, lower alkyl sulfonyl, arylsulfonyl, or lower aralkyl sulfonyl, optionally substituted by one or more substituents; and
  • X and Y are each independently of one another O or S.
  • In the present invention, the cyanide may be a metal cyanide such as sodium cyanide (NaCN) , potassium cyanide (KCN) , zinc cyanide and copper cyanide. Preferably, the cyanide is sodium cyanide or potassium cyanide.
  • In the present invention, the amide solvent is preferably formamide or acetamide. More preferably, the amide solvent is formamide.
  • In the present invention, the protective group may be tert‐butyl, benzyl, 4‐methoxybenzyl, 3, 4‐dimethoxybenzyl, 4‐methylbenzyl, allyl, methallyl, crotyl, methoxymethyl, trimethylsilyl, tert‐butyldimethylsilyl, or tert‐butyldiphenylsilyl.
  • In the present invention, R 1 and R 2 are, each independently of one another, preferably H, C 1‐C 6 alkyl, or phenyl or benzyl, optionally substituted by one or more substituents, and more preferably R 1 is H and R 2 is phenyl.
  • In the present invention, R 3 is preferably tert‐butyl or benzyl, optionally substituted by one or more substituents, more preferably, R 3 is benzyl.
  • In the present invention, R 4 is preferably H, methyl, ethyl, trifluoromethyl, bistrifluoromethylmethyl, trimethylsilyl (‐TMS) , formyl, acetyl, propionyl, benzoyl, 4‐nitrobenzoyl, methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, phenylsulfonyl, toluenesulfonyl or benzylsulfonyl. More preferably, R 4 is H, acetyl, propionyl, benzoyl, toluenesulfonyl, bistrifluoromethylmethyl or trifluoromethanesulfonyl. The most preferably, R 4 is H, benzoyl or acetyl.
  • In one embodiment of the present invention, R 1 is H, R 2 is phenyl, R 3 is benzyl, R 4 is H, X is S, and Y is O.
  • In another embodiment of the present invention, R 1 is H, R 2 is phenyl, R 3 is benzyl, R 4 is benzoyl, bistrifluoromethylmethyl or acetyl, X is S, and Y is O.
  • The stereoisomer of the present invention includes enantiomers and diastereomers. For example, the compound of the formula (I) has the following stereoisomers:
  • and the compound of formula (II) has the following stereoisomers:
  • Wherein R 4 is defined as above.
  • More particularly, the compound of the formula (I) is one of the following stereoisomers:
  • More particularly, the compound of the formula (II) is one of the following stereoisomers:
  • In the process of the present invention, the cyanide may be added in an amount of from 1 mol to 20 mol, preferably from 1.5 mol to 15 mol, more preferably from 2 mol to 10 mol, per 1 mole of the compound of formula (II) .
  • In the present invention, the solvent may be used in the reaction in an amount of from 1 mL to 30 mL, preferably from 2 mL to 20 mL, more preferably from 2 mL to 10 mL, per 1 mole of the compound of formula (II) .
  • Preferably, in the present invention, the reaction is carried out in the absence of a catalyst. Optionally, the present invention may also be carried out in the presence of a catalyst. The catalyst may be selected from a group consisting of trifluoromethanesulfonic acid (HOTf) , trifluoromethanesulfonate esters such as trimethylsilyl trifluoromethanesulfonate (TMSOTf) and tert‐butyldimethylsilyl trifluoromethanesulfonate (t‐BuMe 2SiOTf) , trifluoromethanesulfonate salts such as zinc trifluoromethanesulfonate (Zn (OTf)  2) , iron trifluoromethanesulfonate (Fe (OTf)  3) , copper trifluoromethanesulfonate (Cu (OTf)  2) , ytterbium trifluoromethanesulfonate (Yb (OTf)  3) , scandium trifluoromethanesulfonate (Sc (OTf)  3) , silver trifluoromethanesulfonate (AgOTf) and bismuth trifluoromethanesulfonate (Bi (OTf)  3) , indium halide such as indium bromide (InBr 3) and indium iodide (InI 3) , sliver bis (trifluoromethane sulfonimide) (AgNTf 2) , and trifluoromethansulfonimide, or mixture thereof.
  • In the present invention, an auxiliary reagent may be added into the reaction. Examples of the suitable auxiliary reagent include but are not limited to ammonium chloride, potassium iodide, tetrabutylammonium bromide, 18‐Crown‐6, 4‐Dimethylaminopyridine, and acetic anhydride, and mixture thereof.
  • The reaction of the process of the present invention may be carried out at the temperature of from 0℃to 200℃, preferably from 10℃ to 180℃, more preferably 20℃ to 150℃, such as 50℃ to 120℃ such as 50 ℃, 60 ℃, 80 ℃, 100 ℃ or 120℃, and the most preferably 60℃ to 80℃.
  • The obtained compound of the formula (I) may be isolated and/or purified by a well‐known process in the art and used for the preparation of (+) ‐biotin. Accordingly, the present invention also provides a process for producing (+) ‐biotin which comprises the process for producing the compound of formula (I) as described herein.
  • The process of the present application avoids expensive cyanide reagents and catalysts and provides high yield and/or selectivity.
  • The present invention will be further illustrated by the following examples.
  • Examples
  • In the following examples of the present application, “Ph” is phenyl, “Et” is ethyl, “Bn” is benzyl, “Ac” is acetyl, and “CN” is cyano group.
  • Example 1
  • Compound 1 (150 mg, 0.46 mmol) , KCN (59.8 mg, 2 eq. ) and formamide (2.5 mL) were placed in a 10 mL Schlenk tube. The mixture was stirred at the condition as shown in Table 1 to obtain the desired compound 2. NMR analyzed the conversion and the selectivity with the results as shown in Table 1.
  • Table 1
  • Entries Condition Conversion selectivity
    1 60℃, for 6h 34% 99.9%
    2 80℃, for 3h 68 % 89.3 %
    3 120℃, for 1h 100 % 68.3 %
  • Example 2
  • Compound 1 (150 mg, 0.46 mmol) KCN (300 mg, 10 eq. ) and formamide (5 mL) were placed in a 10 mL Schlenk tube. The mixture was stirred at 60℃ for 7 hours to obtain the desired compound 2. NMR analysis show the conversion is 24%and the selectivity is 99%.
  • Examples 3
  • Compound 3 (150 mg, 0.407 mmol) , KCN (53 mg, 2 eq. ) and formamide (2.5 mL) were placed in a 10 mL Schlenk tube. The mixture was stirred at the condition as shown in Table 2 to obtain the desired compound 2. NMR analyzed the conversion and the selectivity with the results as shown in Table 2.
  • Table 2
  • Entries Condition Conversion selectivity
    5 80℃, for 1.5h 99 % 62.4%
    6 60℃, for 2h 99 % 55.1%
    7 40℃, for 5.5h 99 % 50.7%
  • Example 4
  • Compound 4 (70 mg, 0.163 mmol) , KCN (21 mg, 2 eq. ) and formamide (1.3 mL) were placed in a 10 mL Schlenk tube. The mixture was stirred at 40℃ for 22 hours to obtain the desired compound 2. NMR analysis show the conversion is 100%and the selectivity is 65.4%.
  • Example 5
  • Compound 1 (150 mg, 0.46 mmol) , NaCN (45 mg, 2 eq. ) and formamide (5 mL) were placed in a 10 mL Schlenk tube. The mixture was stirred at 60℃ for 7 hours to obtain the desired compound 2. NMR shows the conversion is 26 %and the selectivity is 99.9%.
  • Comparison Examples
  • Compound 3 (150 mg, 0.407 mmol) , KCN (53 mg, 2 eq. ) and a solvent (2.5 mL) as shown in Table 3 were placed in a 10 mL Schlenk tube. The mixture was stirred at 80℃ overnight to obtain the desired compound 2. NMR analyzed the conversion and the selectivity with the results as shown in Table 3.
  • Table 3
  • Entries solvents Conversion selectivity
    11 dimethylformamide 95% 10.3%
    12 dimethylsulfoxide 100% 18.1%

Claims (13)

  1. A process for producing a compound of formula (I) , or a stereoisomer thereof, or a stereoisomeric mixture thereof, comprising reacting a compound of formula (II) , or a stereoisomer thereof, or a stereoisomeric mixture thereof, with a cyanide in the presence of an amide solvent,
    Wherein:
    R 1 and R 2 are each independently of one another H, lower alkyl, lower cycloalkyl, aryl, or lower aralkyl, optionally substituted by one or more substituents;
    R 3 is H, or a protective group which is suitable for a nitrogen atom;
    R 4 is H, lower alkyl, lower silyl, acyl, lower alkyl sulfonyl, arylsulfonyl, or lower aralkyl sulfonyl, optionally substituted by one or more substituents; and
    X and Y are each independently of one another O or S.
  2. The process of claim 1, wherein the cyanide is a metal cyanide such as sodium cyanide (NaCN) , potassium cyanide (KCN) , zinc cyanide and copper cyanide.
  3. The process of claim 1, wherein the cyanide is sodium cyanide (NaCN) or potassium cyanide (KCN) .
  4. The process of claim 1, wherein the amide solvent is preferably formamide or acetamide.
  5. The process of claim 1, wherein R 1 is H and R 2 is phenyl.
  6. The process of claim 1, wherein R 3 is preferably tert‐butyl or benzyl, optionally substituted by one or more substituents, more preferably, R 3 is benzyl.
  7. The process of claim 1, wherein R 4 is preferably H, methyl, ethyl, trifluoromethyl, bistrifluoromethylmethyl, trimethylsilyl (‐TMS) , formyl, acetyl, propionyl, benzoyl, 4‐nitrobenzoyl, methanesulfonyl, ethanesulfonyl, trifluoromethanesulfonyl, phenylsulfonyl, toluenesulfonyl or benzylsulfonyl.
  8. The process of any one of claims 1‐7, wherein R 1 is H, R 2 is phenyl, R 3 is benzyl, R 4 is H, X is S, and Y is O.
  9. The process of any one of claims 1‐7, wherein R 1 is H, R 2 is phenyl, R 3 is benzyl, R 4 is benzoyl, bistrifluoromethylmethyl or acetyl, X is S, and Y is O.
  10. The process of any one of claims 1‐9, wherein the cyanide is added in an amount of from 1 mol to 20 mol, preferably from 1.5 mol to 15 mol, more preferably from 2 mol to 10 mol, per 1 mole of the compound of formula (II) .
  11. The process of any one of claims 1‐9, wherein the solvent is used in the reaction in an amount of from 1 mL to 30 mL, preferably from 2 mL to 20 mL, more preferably from 2 mL to 10 mL, per 1 mole of the compound of formula (II) .
  12. The process of any one of claims 1‐9, wherein the reaction is carried out in the absence of a catalyst.
  13. A process for producing (+) ‐biotin which comprises the process for producing the compound of formula (I) according to any one of claims 1‐12.
EP21944658.0A 2021-06-11 2021-06-11 Process for producing biotin intermediate Pending EP4352065A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/099885 WO2022257152A1 (en) 2021-06-11 2021-06-11 Process for producing biotin intermediate

Publications (1)

Publication Number Publication Date
EP4352065A1 true EP4352065A1 (en) 2024-04-17

Family

ID=84425596

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21944658.0A Pending EP4352065A1 (en) 2021-06-11 2021-06-11 Process for producing biotin intermediate

Country Status (3)

Country Link
EP (1) EP4352065A1 (en)
CN (1) CN117440956A (en)
WO (1) WO2022257152A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4024692A1 (en) * 1990-08-03 1992-02-06 Merck Patent Gmbh METHOD FOR PRODUCING CYANHYDANTOINES
CN104829627A (en) * 2015-05-08 2015-08-12 东南大学 Chiral hexahydrofuro [2,3-b] furan-3-methylamine, and preparation method and application thereof
US20230069104A1 (en) * 2019-06-28 2023-03-02 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Also Published As

Publication number Publication date
WO2022257152A1 (en) 2022-12-15
CN117440956A (en) 2024-01-23

Similar Documents

Publication Publication Date Title
US7414136B2 (en) Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt
KR840002405A (en) Method for preparing cephalosporin
US10538539B2 (en) Method for preparing 3-((2S, 5S)-4-methylene-5-(3-oxopropyl)tetrahydrofurane-2-yl) propanol derivative, and intermediate therefor
JP3042073B2 (en) Nucleoside derivative and method for producing the same
WO2022257152A1 (en) Process for producing biotin intermediate
DE69918050T2 (en) PROCESS FOR PREPARING (2R, 3S) -3-AMINO-1,2-OXIRANE
US4336206A (en) Process for the manufacture of cyanohydrin acylates of aldehydes
WO2022257151A1 (en) Process for producing biotin intermediate
US7345164B2 (en) Production method of 5′-acyloxynucleoside compound
CN1039423A (en) 2, the preparation method of 2-dehydration-1-(β-D-arabinofuranosyl adenin base) thymus pyrimidine
EP0430096B1 (en) Process for the production of 3,4-epoxybutyrate and intermediate therefor
EP0501426B1 (en) Alpha-methylenecyclopentanone derivative and process for producing the same
EP0257361B1 (en) 5-fluorouridine derivative and preparation of the same
EP0111299B1 (en) Fluorine-containing uridine derivative and preparation and use thereof
US4740598A (en) Conversion of aristeromycin into cyclaradine
EP0219093A2 (en) Process for preparing netilmicin
KR100203729B1 (en) 3'-alkyl or aryl silicaneoxybenzoxazinorifamycin
CN1036580C (en) Process of producing N-alkylacetamides
US5834618A (en) Process for the preparation of 3-amino-2-hydroxy-4-phenylbutyronitrile derivatives
JPH083143A (en) Production of 6-aralkyl substituted pyrimidine derivative
US5525722A (en) Process for producing biocozamycin benzoate
JP2659587B2 (en) 4-aziridinyl pyrimidine derivatives and their production
EP0144484A1 (en) Dicyclopentadiene dicarboxylic acid derivatives and process for their preparation
CN111620829A (en) Synthesis method of 2-methyl-1, 2, 4-triazole-3-amine
FR2681323A1 (en) New amino-2-imidazole derivs. - are intermediates for e.g. girolline, keramadine, hymenidine and oroidine

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR